BMO Capital Markets Reiterates “Outperform” Rating for Pfizer (NYSE:PFE)
The Cerbat Gem - 2024-05-04T16:12:42.000Z

Pfizer (NYSE:PFE – Get Free Report)‘s stock had its “outperform” rating reiterated by research analysts at BMO Capital Markets in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $36.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $33.00. BMO Capital Markets’ […] Read this story